See more : Simo International Société Anonyme (MLSIM.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Poseida Therapeutics, Inc. (PSTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poseida Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Columbia Care Inc. (CCHW.CN) Income Statement Analysis – Financial Results
- Quantum Thinking Limited (8050.HK) Income Statement Analysis – Financial Results
- BioHarvest Sciences Inc. (CNVCF) Income Statement Analysis – Financial Results
- Matrix IT Ltd. (MTRX.TA) Income Statement Analysis – Financial Results
- Jiangsu Boiln Plastics Co., Ltd. (301003.SZ) Income Statement Analysis – Financial Results
Poseida Therapeutics, Inc. (PSTX)
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.70M | 130.36M | 31.24K | 0.00 | 0.00 | 0.00 | 2.99M | 9.77M |
| Cost of Revenue | 156.77M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 0.00 | 0.00 |
| Gross Profit | -92.07M | 125.19M | -4.52M | -2.59M | -1.19M | -689.00K | 2.99M | 9.77M |
| Gross Profit Ratio | -142.29% | 96.03% | -14,472.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 156.77M | 152.90M | 136.73K | 103.52K | 60.39M | 30.88M | 19.10M | 9.86M |
| General & Administrative | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00K |
| SG&A | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.13M |
| Other Expenses | 0.00 | 2.86M | 19.80K | 280.00 | 2.56M | -821.00K | 37.00K | 0.00 |
| Operating Expenses | 194.21M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.00M |
| Cost & Expenses | 179.35M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.22M |
| Interest Income | 0.00 | 6.37M | 3.36M | 3.51M | 1.55M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.67M | 6.37M | 3.36K | 3.51K | 3.55M | 1.80M | 558.00K | 0.00 |
| Depreciation & Amortization | 5.61M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 676.00K | 220.00K |
| EBITDA | -109.04M | -54.77M | -117.06M | -145.48M | -91.68M | -45.12M | -20.88M | -5.12M |
| EBITDA Ratio | -168.52% | -43.79% | -389.32% | 0.00% | 0.00% | 0.00% | -699.50% | -53.53% |
| Operating Income | -129.50M | -59.95M | -141.41K | -126.55K | -85.53M | -41.99M | -19.67M | -5.45M |
| Operating Income Ratio | -200.15% | -45.98% | -452.69% | 0.00% | 0.00% | 0.00% | -658.89% | -55.78% |
| Total Other Income/Expenses | 6.18M | -3.51M | 16.44M | -129.65M | -7.68M | -2.62M | 1.40M | 109.00K |
| Income Before Tax | -123.32M | -63.46M | -124.97K | -129.78K | -86.53M | -44.61M | -20.19M | -5.34M |
| Income Before Tax Ratio | -190.60% | -48.68% | -400.07% | 0.00% | 0.00% | 0.00% | -676.35% | -54.67% |
| Income Tax Expense | 107.00K | 544.00K | -4.53M | -2.58M | 6.11M | -202.00K | -527.00K | -765.00K |
| Net Income | -123.43M | -64.00M | 4.40M | 2.45M | -92.64M | -44.40M | -19.66M | -4.58M |
| Net Income Ratio | -190.76% | -49.10% | 14,097.81% | 0.00% | 0.00% | 0.00% | -658.69% | -46.84% |
| EPS | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| EPS Diluted | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| Weighted Avg Shares Out | 90.19M | 71.91M | 62.18M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
| Weighted Avg Shares Out (Dil) | 90.19M | 71.95M | 62.24M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
Poseida: Early Stage CAR-T And Gene Therapy Developer
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020
Why Poseida Therapeutics Stock Is Popping Today
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports